|
name click to compare prices |
» Shop local, ethical and at the best price on Ethishop |
|
|
|
Business & market
Subsidiaries
shareholder | country | % | source |
|
country | address & contact : production type incentive source |
South Korea | Fujisawa Korea Ltd. 10F. Haesung No.1 Bldg., 942, Kangnam-ku, Seoul & 2-564-3180 : |
Hong-Kong | Fujisawa Hong Kong Ltd. Grand Century Place, 193 Prince Edward Road West, Mongkok, Kowloon & 852-2377-9801 : |
Switzerland | Klinge Pharma AG, Bachstrasse 10, CH-8280 Kreuzlingen & 71-6724882 : |
|
year name | photo position; compensation source |
|
year | employees <> | social impact : country source |
|
year | employees <> | social impact : country source |
|
year | financial misdemeanor | sales | income | | | source |
2003 |
| 3,19 | 0,24 | |   | billion US$ | |
2002 |
| 2,57 | 0,2 | |   | billion US$ | |
2002 |
Fined for fixing the price and sharing the european market for sodium gluconate: 3,6 million euros. |
| | | |   | | Commission Européenne |
2001 |
| 2,36 | 0,16 | |   | billion US$ | |
2000 |
| 2,74 | 0,22 | |   | billion US$ | |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
year | purpose : intermediary/lobby : institution source |
2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington Post |
|
year | purpose : intermediary/lobby : institution source |
|
|
|